Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 5,620 shares at $30.79 ($173K) on 2024-12-10, disclosed to the SEC on 2024-12-12.
Open-market sale of $173k AKRO by Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.79 | 2,810 | $87K | 50.0% |
| 2 | $30.79 | 2,810 | $87K | 50.0% |
| Total | $30.79 avg | 5,620 | $173K | 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |